{"id":"https://openalex.org/W2000767539","doi":"https://doi.org/10.1158/1535-7163.mct-10-0037","title":"Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non\u2013Small Cell Lung Cancer Cell Lines","display_name":"Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non\u2013Small Cell Lung Cancer Cell Lines","alternate_titles":[],"publication_year":2010,"publication_date":"2010-06-29","ids":{"openalex":"https://openalex.org/W2000767539","doi":"https://doi.org/10.1158/1535-7163.mct-10-0037","mag":"2000767539","pmid":"https://pubmed.ncbi.nlm.nih.gov/20587667","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2939826"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-10-0037","doi":"https://doi.org/10.1158/1535-7163.mct-10-0037","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0037","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000767539"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2939826","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060287300","display_name":"Edward B. Garon","orcid":"https://orcid.org/0000-0001-7077-8801","observed_orcids":["https://orcid.org/0000-0001-7077-8801"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Edward B. Garon","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073989429","display_name":"Richard S. Finn","orcid":"https://orcid.org/0000-0003-2494-2126","observed_orcids":["https://orcid.org/0000-0003-2494-2126"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard S. Finn","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015716019","display_name":"Wylie Hosmer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wylie Hosmer","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066999153","display_name":"Judy Dering","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy Dering","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110850","display_name":"Charles Ginther","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Ginther","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043976705","display_name":"Shahriar Adhami","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shahriar Adhami","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004811009","display_name":"Naeimeh Kamranpour","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naeimeh Kamranpour","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111724065","display_name":"Sharon L. Pitts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Pitts","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009971985","display_name":"Amrita J. Desai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amrita Desai","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070990818","display_name":"David A. Elashoff","orcid":"https://orcid.org/0000-0002-5865-8580","observed_orcids":["https://orcid.org/0000-0002-5865-8580"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Elashoff","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030763134","display_name":"Tim French","orcid":"https://orcid.org/0000-0002-0748-8040","observed_orcids":["https://orcid.org/0000-0002-0748-8040"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tim French","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039299082","display_name":"Paul D. Smith","orcid":"https://orcid.org/0000-0002-2812-5978","observed_orcids":["https://orcid.org/0000-0002-2812-5978"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Smith","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis J. Slamon","raw_affiliation_strings":["Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Department of Medicine, Division of Hematology/Oncology, and 2Department of Medicine, Division of General Internal Medicine, Geffen School of Medicine at UCLA, Los Angeles, California; and 3AstraZeneca R&D, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5060287300"],"corresponding_institution_ids":["https://openalex.org/I161318765"],"apc_list":null,"apc_paid":null,"fwci":2.511,"has_fulltext":false,"cited_by_count":71,"citation_normalized_percentile":{"value":0.89934343,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"9","issue":"7","first_page":"1985","last_page":"1994"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selumetinib","display_name":"selumetinib","score":1.0},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.7269999980926514},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9150000214576721},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/breast-cancer-cell-lines","display_name":"breast cancer cell lines","score":0.9629999995231628},{"id":"https://openalex.org/keywords/raf-mutations","display_name":"RAF mutations","score":0.765999972820282},{"id":"https://openalex.org/keywords/ras-mutations","display_name":"RAS mutations","score":0.8299999833106995},{"id":"https://openalex.org/keywords/phosphoinositide-3-kinase-pathway","display_name":"phosphatidylinositol 3-kinase pathway","score":0.8880000114440918},{"id":"https://openalex.org/keywords/gene-expression-profiling","display_name":"gene expression profiling","score":0.8889999985694885},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.46299999952316284}],"concepts":[{"id":"https://openalex.org/C2776087337","wikidata":"https://www.wikidata.org/wiki/Q7448840","display_name":"Selumetinib","level":5,"score":0.8877866864204407},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6062287092208862},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5774504542350769},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5752028226852417},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5198107957839966},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4655246436595917},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4404389560222626},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4092141091823578},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.2981051206588745},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2835271954536438},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.16932928562164307},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.11882683634757996}],"mesh":[{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015153","descriptor_name":"Blotting, Western","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016000","descriptor_name":"Cluster Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019950","descriptor_name":"Mitogen-Activated Protein Kinase 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D019950","descriptor_name":"Mitogen-Activated Protein Kinase 1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019950","descriptor_name":"Mitogen-Activated Protein Kinase 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020128","descriptor_name":"Inhibitory Concentration 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020411","descriptor_name":"Oligonucleotide Array Sequence Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020869","descriptor_name":"Gene Expression Profiling","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D048052","descriptor_name":"Mitogen-Activated Protein Kinase 3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048052","descriptor_name":"Mitogen-Activated Protein Kinase 3","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D048052","descriptor_name":"Mitogen-Activated Protein Kinase 3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D048490","descriptor_name":"raf Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-10-0037","doi":"https://doi.org/10.1158/1535-7163.mct-10-0037","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0037","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20587667","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20587667","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:2121456","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2939826","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:2939826","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2939826/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2121456","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2939826","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4344410982","display_name":"UCLA SPORE IN LUNG CANCER","funder_award_id":"P50CA090388","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W41965769","https://openalex.org/W1575240385","https://openalex.org/W1961026612","https://openalex.org/W1963713713","https://openalex.org/W1974091059","https://openalex.org/W1981711832","https://openalex.org/W1988698939","https://openalex.org/W2001999652","https://openalex.org/W2004136952","https://openalex.org/W2014977126","https://openalex.org/W2045300715","https://openalex.org/W2069457194","https://openalex.org/W2080686146","https://openalex.org/W2103382943","https://openalex.org/W2112037424","https://openalex.org/W2118004874","https://openalex.org/W2120492882","https://openalex.org/W2121389354","https://openalex.org/W2123611729","https://openalex.org/W2124301770","https://openalex.org/W2124662474","https://openalex.org/W2128445526","https://openalex.org/W2129429534","https://openalex.org/W2133776282","https://openalex.org/W2142799999","https://openalex.org/W2144169031","https://openalex.org/W2156509877","https://openalex.org/W2157016650","https://openalex.org/W2160067245","https://openalex.org/W2162147795","https://openalex.org/W2172248787","https://openalex.org/W2318605753","https://openalex.org/W4248204656"],"related_works":["https://openalex.org/W2128445526","https://openalex.org/W2135707008","https://openalex.org/W2065920166","https://openalex.org/W2090183017","https://openalex.org/W2062689591","https://openalex.org/W2478552722","https://openalex.org/W1649308583","https://openalex.org/W1601243762","https://openalex.org/W1974284935","https://openalex.org/W2078354705"],"abstract_inverted_index":{"Selumetinib":[0],"(AZD6244;":[1],"ARRY-142886)":[2],"is":[3],"a":[4,78,163],"tight-binding,":[5],"uncompetitive":[6],"inhibitor":[7],"of":[8,25,64,72,104,106,166,185],"mitogen-activated":[9],"protein":[10],"kinase":[11],"kinases":[12],"(MEK)":[13],"1":[14],"and":[15,34,70,82,93,120,125,190,199],"2":[16],"currently":[17],"in":[18,27,49,62,85,96,159,168,187],"clinical":[19,183],"development.":[20],"We":[21],"evaluated":[22],"the":[23,107],"effects":[24],"selumetinib":[26,156,186],"31":[28,65],"human":[29,36],"breast":[30,66,86,188],"cancer":[31,40,67,87,189],"cell":[32,38,42,68,75,88,98,109,138],"lines":[33,43,69,89,99,110],"43":[35,73],"non-small":[37],"lung":[39],"(NSCLC)":[41],"to":[44,52,127,145,155,174],"identify":[45,146],"characteristics":[46],"correlating":[47],"with":[48,77,111,152],"vitro":[50],"sensitivity":[51,81,126,154],"MEK":[53,119,128],"inhibition.":[54,129],"IC(50)":[55],"<1":[56],"micromol/L":[57],"(considered":[58],"sensitive)":[59],"was":[60,172],"seen":[61,158],"5":[63],"15":[71],"NSCLC":[74,97,108,191],"lines,":[76],"correlation":[79],"between":[80,118],"raf":[83,198],"mutations":[84,95],"(P":[90,100],"=":[91,101],"0.022)":[92],"ras":[94,200],"0.045).":[102],"Evaluation":[103],"27":[105],"Western":[112],"blots":[113],"showed":[114],"no":[115],"clear":[116],"association":[117],"phosphoinositide":[121],"3-kinase":[122],"pathway":[123],"activation":[124],"Baseline":[130],"gene":[131,142],"expression":[132,143,171],"profiles":[133],"were":[134,157],"generated":[135],"for":[136],"each":[137],"line":[139],"using":[140],"Agilent":[141],"arrays":[144],"additional":[147],"predictive":[148],"markers.":[149],"Genes":[150],"associated":[151],"differential":[153,170],"both":[160,175],"histologies,":[161],"including":[162],"small":[164],"number":[165],"genes":[167],"which":[169],"common":[173],"histologies.":[176],"In":[177],"total,":[178],"these":[179],"results":[180],"suggest":[181],"that":[182],"trials":[184],"might":[192],"select":[193],"patients":[194],"whose":[195],"tumors":[196],"harbor":[197],"mutations,":[201],"respectively.":[202]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000767539","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":14},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
